Sign up to save your podcasts
Or
Share Personalizing First-Line Therapy for CLL
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Personalizing First-Line Therapy for CLL
CME credits: 0.25
Valid until: 30-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/
This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetoclax-based regimens, while highlighting considerations such as comorbidities, toxicities, IGHV status, and TP53 aberrations. They examine recent and emerging data from trials including CLL17, AMPLIFY, and BRUIN CLL-313, as well as novel agents. The conversation underscores the importance of personalized therapy selection in frontline CLL care.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 30-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/
This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetoclax-based regimens, while highlighting considerations such as comorbidities, toxicities, IGHV status, and TP53 aberrations. They examine recent and emerging data from trials including CLL17, AMPLIFY, and BRUIN CLL-313, as well as novel agents. The conversation underscores the importance of personalized therapy selection in frontline CLL care.
=